Immuno-oncology Bispecific nanobody targeting PD-L1 and CXCR4 shows efficacy in pancreatic tumor models Dec. 1, 2022 Researchers from Jecho Laboratories Inc. and Shanghai Jiao Tong University reported the discovery of a novel anti-PD-L1/CXCR4 bispecific nanobody, BsNb PX-4, being developed for the treatment of cancer.Read More
